The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.

Détails

Ressource 1Télécharger: BIB_0DF65F1D66D1.P001.pdf (369.45 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_0DF65F1D66D1
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Périodique
Blood Reviews
Auteur(s)
Kaiser-Guignard J., Canellini G., Lion N., Abonnenc M., Osselaer J.C., Tissot J.D.
ISSN
1532-1681 (Electronic)
ISSN-L
0268-960X
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
28
Numéro
6
Pages
235-241
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish Document Type: Review
Résumé
Since 1990, several techniques have been developed to photochemically inactivate pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The three most common methods are amotosalen/UVA (INTERCEPT Blood System), riboflavin/UVA-UVB (MIRASOL PRT), and UVC (Theraflex-UV). We review the biology of pathogen inactivation methods, present their efficacy in reducing pathogens, discuss their impact on the functional aspects of treated platelets, and review clinical studies showing the clinical efficiency of the pathogen inactivation methods and their possible toxicity.
Pubmed
Web of science
Open Access
Oui
Création de la notice
02/01/2015 9:36
Dernière modification de la notice
20/08/2019 12:35
Données d'usage